p57-discordant villi in hydropic products of conception: a clinicopathological study of 70 cases.
Androgenetic/biparental mosaicism
Discordant
Divergent
Hydatidiform mole
p57 immunohistochemistry
Journal
Human pathology
ISSN: 1532-8392
Titre abrégé: Hum Pathol
Pays: United States
ID NLM: 9421547
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
30
03
2020
revised:
20
04
2020
accepted:
27
04
2020
pubmed:
11
5
2020
medline:
13
2
2021
entrez:
11
5
2020
Statut:
ppublish
Résumé
p57 immunostaining is performed on hydropic products of conception to diagnose hydatidiform moles (HMs), which can progress to gestational trophoblastic neoplasia. Partial hydatidiform mole (PHM) and hydropic abortion (HA) display positive staining in stromal and cytotrophoblastic cells, whereas complete hydatidiform mole (CHM) is characterized by loss of p57 expression in both cell types. In some cases, an aberrant pattern is observed, called discordant p57 expression, with positive cytotrophoblast staining and negative stromal staining, or vice versa. The aim of this study was to describe the clinical, biological, and pathological characteristics of p57-discordant villi (p57DV) and other associated populations in cases of divergent p57 expression and to compare the evolutions of p57DV-associated and classic CHMs. Seventy cases of p57DV diagnosed by referent pathologists were divided into two groups, G1: p57DV ± non-CHM component (n = 22) and G2: p57DV + CHM component (n = 48). p57DV morphology was similar in the two groups. Observation of more than two populations and hybrid villi on p57 immunostaining were significantly more frequent in G2. The clinical, ultrasound, and biological presentations of p57DV-associated and classic CHMs were similar. The initial pathological diagnosis was more frequently incorrect, missing the CHM component, for the p57DV-associated CHMs. Molecular genotyping was informative in seven cases and identified as androgenetic/biparental mosaicism in four cases. These results show that p57DV are a diagnostic challenge for pathologists and that most are associated with a CHM component. However, the clinical management of p57DV-associated CHMs should be the same as that of classic CHMs.
Identifiants
pubmed: 32387104
pii: S0046-8177(20)30080-0
doi: 10.1016/j.humpath.2020.04.011
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
CDKN1C protein, human
0
Cyclin-Dependent Kinase Inhibitor p57
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
18-30Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.